Skip to content
← Holders

Aisling Capital Management LP

What Aisling Capital Management LP reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 1766721 · Filed Nov 12, 2026

Positions
14
Reported value
$299.3M
Opened
0
Closed
0
Other managers included
0

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Sep 30, 2025$456.4M
    14 positions
  2. Dec 31, 2025$478.9M
    13 positions
  3. Mar 31, 2026$476.3M
    13 positions
  4. Jun 30, 2026$471.6M
    14 positions
  5. Sep 30, 2026$299.3M
    14 positions
SecuritySharesChangeValueOf portfolio
BBIOBridgeBio Pharma, Inc.
3.1M−32.7%$203.3M67.9%
SNDXSyndax Pharmaceuticals Inc
1.3M±0%$24.8M8.3%
CMPSCOMPASS Pathways plc
1.7M+20.9%$21.6M7.2%
GLUEMonte Rosa Therapeutics, Inc.
1.6M±0%$18.6M6.2%
BCAXBicara Therapeutics Inc.
548.9K−3.5%$10.2M3.4%
URGNUroGen Pharma Ltd.
108K±0%$4.4M1.5%
BBOTBridgeBio Oncology Therapeutics, Inc.
1M±0%$4.1M1.4%
EPRXEupraxia Pharmaceuticals Inc.
325K±0%$3M1%
BMEABiomea Fusion, Inc.
2M±0%$2.7M0.9%
ACRSAclaris Therapeutics, Inc.
434.5K±0%$2.3M0.8%
SRRKScholar Rock Holding Corp
42K−45.4%$2M0.7%
VTVTvTv Therapeutics Inc.
58.8K+17.5%$1.8M0.6%
MRKRMarker Therapeutics, Inc.
325.4K±0%$348.1K0.1%
OKUROnKure Therapeutics, Inc.
88.6K±0%$241.5K0.1%